Dapagliflozin for prednisone-induced hyperglycemia in acute exacerbation of chronic obstructive pulmonary disease.
Diabetes Obes Metab. 2018 Jan 05;:
Authors: Gerards MC, Venema GE, Patberg KW, Kross M, Potter van Loon BJ, Hageman IMG, Snijders D, Brandjes DPM, Hoekstra JBL, Vriesendorp TM, Gerdes VEA
This study aimed to compare the effectiveness and safety of add-on treatment with dapagliflozin to placebo in subjects with prednisone-induced hyperglycemia during treatment for acute exacerbation of chronic obstructive pulmonary disease (AECOPD). We enrolled 46 patients hospitalized for an AECOPD in a multicenter double-blind randomized controlled study in which add-on treatment with dapagliflozin 10 mg was compared to placebo. Glycemic control and incidence of hypoglycemia were measured through a blinded subcutaneous continuous glucose measurement device. Subjects in the dapagliflozin group, spent 54 ± 27.7% of the time in target range (3.9-10 mmol/L) and this was 53.6 ± 23.4% in the placebo group (p = 0.96). Mean glucose concentration was 10.1 mmol/L in the dapagliflozin group and 10.4 mmol/L in the placebo group (p = 0.66). One patient using dapagliflozin and 2 patients using placebo experienced a symptomatic hypoglycemia. Treatment with dapagliflozin was safe and there was no difference in risk of hypoglycemia compared to placebo. Dapagliflozin did not result in better glycemic control compared to placebo in patients with prednisone-induced hyperglycemia during AECOPD.
PMID: 29316157 [PubMed - as supplied by publisher]